SA News • Dec. 31, 2014
Dec. 31, 2014, 10:25 AM
- Thinly-traded nano cap Brainstorm Cell Therapeutics (BCLI +22.7%) jumps on a 6x surge in volume in response to CEO Tony Fiorino's positive comments about the final results from the Phase 2a study of NurOwn in ALS patients.
- Management will host a conference call on January 5 at 8:30 am ET to discuss the data.
- Previously: BrainStorm to start Phase 2 ALS trial (April 28)
- Stem cell-related tickers: (CUR +3.8%)(STEM)(NBS +0.5%)(OTCQB:ISCO +1.4%)(PSTI +2.2%)(OTCQB:NVIV -1.5%)(FCSC +1.6%)
Nov. 13, 2014, 10:51 AM
Nov. 7, 2014, 9:06 AM
Nov. 4, 2014, 12:32 PM| Comment!
ISCO vs. ETF Alternatives
International Stem Cell Corporation is a California-based biotechnology company developing novel stem cell based therapies and biomedical products. ISCO's core technology, parthenogenesis, creates pluripotent human stem cells from unfertilized eggs. These stem cells avoid ethical issues... More
Other News & PR